A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder



Status:Recruiting
Conditions:Neurology, Psychiatric
Therapuetic Areas:Neurology, Psychiatry / Psychology
Healthy:No
Age Range:18 - 55
Updated:2/17/2019
Start Date:January 16, 2019
End Date:May 2020

Use our guide to learn which trials are right for you!

A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

This study evaluates the efficacy, safety, and tolerability of centanafadine
sustained-release tablets in adults with ADHD. Patients will either receive a twice-daily
dose of centanafadine sustained-release tablets, or twice-daily placebo.

Screening & Washout Period: up to 28 days Investigational Treatment Period: 49 days Follow-up
Period : 7 days or 10 days

Inclusion Criteria:

- Subjects must meet the Diagnostic and Statistical Manual of Mental Disorders Fifth
Edition (DSM-5) criteria for ADHD (including predominantly inattentive presentation,
hyperactive presentation, or combined presentation) as confirmed by the Adult ADHD
Clinical Diagnostic Scale (ACDS) Version 1.2. To confirm that ADHD is the primary
diagnosis, the Mini International Neuropsychiatric Interview (MINI) will be used to
identify and exclude other psychiatric conditions which would preclude enrollment.

- Subjects who were not receiving any pharmacological treatment for ADHD must have an
Adult ADHD Investigator Symptom Rating Scale (AISRS) score of ≥ 28 at screening and
baseline. Subjects who were receiving pharmacological treatment for ADHD at screening
must have a minimum AISRS score of ≥ 22 at screening, and a score of ≥ 28 at baseline.

- All subjects must be willing to discontinue all prohibited psychotropic medications
starting from the time of signing the informed consent through the 7-day follow-up
period. Subjects that do not rollover into Trial 405-201-00015 must be willing to
discontinue all prohibited psychotropic medications starting from the time of signing
the informed consent until after the follow-up telephone call 10 days after the last
dose of IMP.

- Subjects must have a Clinical Global Impression-Severity of Illness Scale (CGI-S)
score of ≥ 4 (≥ moderate impairment) at baseline.

Exclusion Criteria:

- Subject has a DSM-5 Diagnosis of Other Specified or Unspecified Attention
Deficit/Hyperactivity Disorder.

- Subject has a current comorbid psychiatric disorder that either could be expected to
require treatment with medications prohibited in this trial, or to confound efficacy
or safety assessments. Examples include, but are not limited to, psychotic disorder,
bipolar disorder, generalized anxiety disorder, obsessive-compulsive disorder, panic
disorder, a current major depressive episode, or posttraumatic stress disorder, as
established by the MINI.

- In the opinion of the investigator, subject has not derived significant therapeutic
benefit from 2 or more ADHD therapies of 2 different classes (eg, amphetamine and
methylphenidate) given with an acceptable dose and duration of adulthood (aged 18 or
older). NOTE: If subject has not derived significant therapeutic benefit due to an
inability to tolerate side effects, eligibility can be discussed on case-by-case basis
with the medical monitor.

- Subjects that have a positive alcohol test (via breathalyzer or blood), a positive
drug screen for cocaine, or other illicit drugs (excluding marijuana). Subjects with a
positive drug screen for confirmed prescription or over-the-counter (OTC) use of ADHD
medications at screening will be required to undergo a washout period. NOTE: Subjects
that test positive for marijuana may be permitted to be enrolled if they have no
evidence of a substance use disorder, and if they agree to refrain from use for the
duration of the trial. Allowance for subjects testing positive for marijuana at
screening require explicit approval from the medical monitor.

- In the opinion of the investigator, the subject is unable to adhere to the treatment
regimen or other requirements outlined in the protocol.
We found this trial at
25
sites
436 North Roxbury Drive
Beverly Hills, California 90210
Phone: 424-284-3171
?
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
1100 Johnson Ferry Road
Atlanta, Georgia 30342
404-851-9934
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
One Utah Avenue
Cherry Hill, New Jersey 08002
856-857-9500
?
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
3212 Cove Bend Drive
Tampa, Florida 33613
Phone: 813-971-8311
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Allentown, Pennsylvania 18104
Phone: 610-820-0342
?
mi
from
Allentown, PA
Click here to add this to my saved trials
3570 Warrensville Center Road
Beachwood, Ohio 44122
Phone: 216-526-1843
?
mi
from
Beachwood, OH
Click here to add this to my saved trials
Bradenton, Florida
Phone: 941-756-8680
?
mi
from
Bradenton, FL
Click here to add this to my saved trials
Charleston, South Carolina 29405
Phone: 843-576-6750
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Charlotte, North Carolina 28210
Phone: 800-785-3150
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Dallas, Texas 75231
Phone: 214-369-2600
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Encino, California 91316
Phone: 818-705-7451
?
mi
from
Encino, CA
Click here to add this to my saved trials
Lake Charles, Louisiana 70601
Phone: 337-564-6405
?
mi
from
Lake Charles, LA
Click here to add this to my saved trials
Lauderhill, Florida 33319
Phone: 954-990-6326
?
mi
from
Lauderhill, FL
Click here to add this to my saved trials
Lemon Grove, California 91945
Phone: 619-303-6130
?
mi
from
Lemon Grove, CA
Click here to add this to my saved trials
8550 Cuthills Circle
Lincoln, Nebraska 68526
Phone: 402-817-2235
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
Marietta, Georgia 30060
Phone: 770-422-2846
?
mi
from
Marietta, GA
Click here to add this to my saved trials
New York, New York 10128
Phone: 212-595-5012
?
mi
from
New York, NY
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73103
Phone: 405-235-8188
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Orlando, Florida 32806
Phone: 407-425-5100
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Portland, Oregon 97210
Phone: 503-972-9837
?
mi
from
Portland, OR
Click here to add this to my saved trials
Portland, Oregon 97210
Phone: 503-276-6224
?
mi
from
Portland, OR
Click here to add this to my saved trials
Rochester, New York 14618
Phone: 585-241-9670
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Rochester Hills, Michigan 48307
Phone: 248-608-8800
?
mi
from
Rochester Hills, MI
Click here to add this to my saved trials
Tampa, Florida 33609
Phone: 813-849-5566
?
mi
from
Tampa, FL
Click here to add this to my saved trials
3300 Seymour Highway
Wichita Falls, Texas 76309
Phone: 940-322-1131
?
mi
from
Wichita Falls, TX
Click here to add this to my saved trials